Literature DB >> 27284054

The SLC28 (CNT) and SLC29 (ENT) nucleoside transporter families: a 30-year collaborative odyssey.

James D Young1.   

Abstract

Specialized nucleoside transporter (NT) proteins are required for passage of nucleosides and hydrophilic nucleoside analogues across biological membranes. Physiologic nucleosides serve as central salvage metabolites in nucleotide biosynthesis, and nucleoside analogues are used as chemotherapeutic agents in the treatment of cancer and antiviral diseases. The nucleoside adenosine modulates numerous cellular events via purino-receptor cell signalling pathways. Human NTs are divided into two structurally unrelated protein families: the SLC28 concentrative nucleoside transporter (CNT) family and the SLC29 equilibrative nucleoside transporter (ENT) family. Human CNTs are inwardly directed Na(+)-dependent nucleoside transporters found predominantly in intestinal and renal epithelial and other specialized cell types. Human ENTs mediate bidirectional fluxes of purine and pyrimidine nucleosides down their concentration gradients and are ubiquitously found in most, possibly all, cell types. Both protein families are evolutionarily old: CNTs are present in both eukaryotes and prokaryotes; ENTs are widely distributed in mammalian, lower vertebrate and other eukaryote species. This mini-review describes a 30-year collaboration with Professor Stephen Baldwin to identify and understand the structures and functions of these physiologically and clinically important transport proteins.
© 2016 The Author(s). published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  SLC28; SLC29; concentrative nucleoside transporter (CNT); equilibrative nucleoside transporter (ENT); nucleoside transporter

Mesh:

Substances:

Year:  2016        PMID: 27284054     DOI: 10.1042/BST20160038

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  28 in total

Review 1.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

Review 2.  Determinants of nutrient limitation in cancer.

Authors:  Mark R Sullivan; Matthew G Vander Heiden
Journal:  Crit Rev Biochem Mol Biol       Date:  2019-06-04       Impact factor: 8.250

Review 3.  Neural Signaling Metabolites May Modulate Energy Use in Hibernation.

Authors:  Kelly L Drew; Carla Frare; Sarah A Rice
Journal:  Neurochem Res       Date:  2016-11-23       Impact factor: 3.996

4.  The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors.

Authors:  Christine R Cuthbertson; Hui Guo; Armita Kyani; Joseph T Madak; Zahra Arabzada; Nouri Neamati
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-23

Review 5.  A Historical Review of Brain Drug Delivery.

Authors:  William M Pardridge
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

6.  Coordination of ENT2-dependent adenosine transport and signaling dampens mucosal inflammation.

Authors:  Carol M Aherne; Colm B Collins; Caroline R Rapp; Kristine E Olli; Loni Perrenoud; Paul Jedlicka; Jessica L Bowser; Tingting W Mills; Harry Karmouty-Quintana; Michael R Blackburn; Holger K Eltzschig
Journal:  JCI Insight       Date:  2018-10-18

Review 7.  A guide to plasma membrane solute carrier proteins.

Authors:  Mattia D Pizzagalli; Ariel Bensimon; Giulio Superti-Furga
Journal:  FEBS J       Date:  2020-09-18       Impact factor: 5.542

Review 8.  Glial Purinergic Signaling in Neurodegeneration.

Authors:  Marie J Pietrowski; Amr Ahmed Gabr; Stanislav Kozlov; David Blum; Annett Halle; Kevin Carvalho
Journal:  Front Neurol       Date:  2021-05-14       Impact factor: 4.003

Review 9.  Adenosine Signaling in Mast Cells and Allergic Diseases.

Authors:  Lucia Garcia-Garcia; Laia Olle; Margarita Martin; Jordi Roca-Ferrer; Rosa Muñoz-Cano
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

10.  Equilibrative nucleoside transporter 1 inhibition rescues energy dysfunction and pathology in a model of tauopathy.

Authors:  Ching-Pang Chang; Ya-Gin Chang; Pei-Yun Chuang; Thi Ngoc Anh Nguyen; Kuo-Chen Wu; Fang-Yi Chou; Sin-Jhong Cheng; Hui-Mei Chen; Lee-Way Jin; Kevin Carvalho; Vincent Huin; Luc Buée; Yung-Feng Liao; Chun-Jung Lin; David Blum; Yijuang Chern
Journal:  Acta Neuropathol Commun       Date:  2021-06-22       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.